Literature DB >> 19340676

The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence.

David Walters1, Jason P Connor, Gerald F X Feeney, Ross McD Young.   

Abstract

The purpose of this study was to evaluate the comparative cost of treating alcohol dependence with either cognitive behavioral therapy (CBT) alone or CBT combined with naltrexone (CBT+naltrexone). Two hundred ninety-eight outpatients dependent on alcohol who were consecutively treated for alcohol dependence participated in this study. One hundred seven (36%) patients received adjunctive pharmacotherapy (CBT+naltrexone). The Drug Abuse Treatment Cost Analysis Program was used to estimate treatment costs. Adjunctive pharmacotherapy (CBT+naltrexone) introduced an additional treatment cost and was 54% more expensive than CBT alone. When treatment abstinence rates (36.1% CBT; 62.6% CBT+naltrexone) were applied to cost effectiveness ratios, CBT+naltrexone demonstrated an advantage over CBT alone. There were no differences between groups on a preference-based health measure (SF-6D). In this treatment center, to achieve 100 abstainers over a 12-week program, 280 patients require CBT compared with 160 CBT+naltrexone. The dominant choice was CBT+naltrexone based on modest economic advantages and significant efficiencies in the numbers needed to treat.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19340676     DOI: 10.1080/10550880902772456

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  8 in total

Review 1.  Cognitive behavioral therapy for substance use disorders.

Authors:  R Kathryn McHugh; Bridget A Hearon; Michael W Otto
Journal:  Psychiatr Clin North Am       Date:  2010-09

2.  Longitudinal association of preference-weighted health-related quality of life measures and substance use disorder outcomes.

Authors:  Jeffrey M Pyne; Shanti Tripathi; Michael French; Kathryn McCollister; Richard C Rapp; Brenda M Booth
Journal:  Addiction       Date:  2011-03       Impact factor: 6.526

Review 3.  The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.

Authors:  Michael Sonntag; Hans-Helmut König; Alexander Konnopka
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

4.  Using the SF-6D to measure the impact of alcohol dependence on health-related quality of life.

Authors:  Jacinto Mosquera Nogueira; Eva Rodríguez-Míguez
Journal:  Eur J Health Econ       Date:  2014-09-06

Review 5.  Improving clinical outcomes for naltrexone as a management of problem alcohol use.

Authors:  Gary K Hulse
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

6.  The pharmacotherapy of alcohol dependence: a state of the art review.

Authors:  Avinash De Sousa
Journal:  Mens Sana Monogr       Date:  2010-01

7.  LAT software induced savings on medical costs of alcohol addicts' care--results from a matched-pairs case-control study.

Authors:  Mihajlo Jakovljevic; Mirjana Jovanovic; Nemanja Rancic; Benjamin Vyssoki; Natasa Djordjevic
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

8.  Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.

Authors:  Monica Bolton; Alex Hodkinson; Shivani Boda; Alan Mould; Maria Panagioti; Sarah Rhodes; Lisa Riste; Harm van Marwijk
Journal:  BMC Med       Date:  2019-01-15       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.